2018
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original Research
2013
Treatment strategies for peripheral T-cell lymphomas
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAggressive first-line therapyAutologous stem cell transplantationConventional lymphoma therapyFirst-line therapyMajority of patientsStem cell transplantationSignal transduction inhibitorsHistone deacetylase inhibitorsFuture novel approachesLine therapyTransplant candidatesImproved survivalRelevant pathwaysAggressive diseaseCell transplantationInferior outcomesLymphoma therapyTransduction inhibitorsTreatment strategiesDeacetylase inhibitorsMonoclonal antibodiesMolecular profilingHeterogeneous group
2012
Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clinical Lymphoma Myeloma & Leukemia 2012, 12: 238-243. PMID: 22542448, DOI: 10.1016/j.clml.2012.01.010.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalToxicity-related discontinuationProgression-free survivalIndependent central reviewMedian survivalInvestigator assessmentMycosis fungoidesCentral reviewMedian durationAggressive diseaseRetrospective analysisGrade 4 adverse eventsPrior systemic therapySubgroup efficacy analysesObjective response rateTransformed Mycosis FungoidesPROPEL StudyAdverse eventsObjective responseSystemic therapyCutaneous lesionsEfficacy analysisPoor prognosisTreatment optionsMedian number
2011
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma
Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opinion On Drug Metabolism & Toxicology 2011, 7: 1141-1152. PMID: 21726160, DOI: 10.1517/17425255.2011.595404.Peer-Reviewed Original ResearchMeSH KeywordsAminopterinAntineoplastic AgentsClinical Trials as TopicDrug Evaluation, PreclinicalFolic Acid AntagonistsHumansLymphoma, T-CellConceptsPeripheral T-cell lymphomaT-cell lymphomaRefractory peripheral T-cell lymphomaPhase I/II trialEarly phase I/II trialsCutaneous T-cell lymphomaAggressive T-cell lymphomaT-cell lymphoma subtypesFrequent adverse eventsStem cell transplantationT-cell neoplasmsII trialAdverse eventsMost patientsHodgkin's diseasePreclinical findingsClinical efficacyLymphoma trialsPoor outcomeConventional therapyHodgkin's lymphomaReversible thrombocytopeniaHematologic malignanciesClinical trialsClinical studiesPeripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biologyRelapsed and refractory PTCL—into the therapeutic abyss
Foss F. Relapsed and refractory PTCL—into the therapeutic abyss. Nature Reviews Clinical Oncology 2011, 8: 321-322. PMID: 21468128, DOI: 10.1038/nrclinonc.2011.51.Peer-Reviewed Original Research